Advertisement

Kimberly L. Blackwell, MD

Articles

Dr. Blackwell on the Treatment of Young Women With Breast Cancer

April 12th 2018

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the treatment of young women with breast cancer.

Dr. Blackwell Discusses the HER2CLIMB Study in HER2+ Breast Cancer

March 7th 2018

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the HER2CLIMB study in patients with HER2-positive breast cancer.

Dr. Blackwell Discusses Tucatinib in HER2+ Breast Cancer

February 3rd 2018

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the role of tucatinib (ONT-380) for patients with HER2-positive breast cancer.

Dr. Blackwell on the Impact of the CLEOPATRA and MARIANNE Studies in HER2+ Breast Cancer

November 1st 2016

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the lasting impact that the CLEOPATRA and MARIANNE studies have had on the treatment landscape in HER2-positive breast cancer.

Dr. Blackwell on Treatment Landscape of HER2+ Breast Cancer

October 19th 2016

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the available treatments for patients with HER2-positive breast cancer, as well as other agents that are in development.

Dr. Blackwell on Late Recurrences in Patients With Breast Cancer

March 10th 2016

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses using the word "cure" in patients with breast cancer who have not had recurrences of disease.

Dr. Blackwell on Margetuximab for HER2+ Breast Cancer

January 19th 2016

Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses the mechanism of action for margetuximab (MGAH22-01) and discusses its potential as a treatment of patients with HER2-positive breast cancer.

Dr. Blackwell on Emerging Therapies in TNBC

November 6th 2015

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses emerging therapies for patients with triple-negative breast cancer.

Dr. Blackwell Discusses the T-DM1 EMILIA Trial Endpoints

June 26th 2012

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial Coprimary Endpoints

Dr. Blackwell Discusses the T-DM1 EMILIA Trial

June 3rd 2012

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

Advertisement
Advertisement